PSAbloedtest

The PSAbloedtest is a blood test that measures the concentration of prostate‑specific antigen (PSA), a protein produced mainly by cells of the prostate gland. PSA is released into the bloodstream in small amounts and rises when prostate tissue is stimulated or damaged. The test is most commonly used to help detect and monitor prostate cancer, although elevated PSA levels can also indicate benign prostatic hyperplasia, prostatitis or recent prostate manipulation.

Procedure and methodology

Blood is drawn from a vein in the arm and processed in a laboratory. Modern analyzers use immunoassay techniques, usually chemiluminescent or electrochemiluminescent methods, to quantify PSA. The result is expressed in nanograms of PSA per milliliter of blood (ng/mL). For standard screening, a PSA threshold of 4.0 ng/mL has traditionally been used to trigger further investigation, although many clinicians now employ age‑specific or risk‑adjusted cut‑offs.

Interpretation of results

A PSA level below 4.0 ng/mL is generally considered normal, but this cutoff does not guarantee the absence of disease. Values between 4.0 and 10.0 ng/mL are usually regarded as abnormal and may warrant a repeat test or additional diagnostic procedures such as digital rectal examination, transrectal ultrasound or prostate biopsy. Levels above 10.0 ng/mL most often prompt more urgent evaluation. Recent evidence suggests that causes of false‑positive results (e.g., recent ejaculation, catheter use, or urinary tract infections) should be ruled out before interpreting a high PSA.

Limitations and controversies

The PSA test is not specific for cancer; many benign conditions can elevate PSA. Consequently, prostate biopsy is required for definitive diagnosis. Overdiagnosis and overtreatment of clinically insignificant tumors remain concerns, leading some health organizations to recommend shared decision‑making when considering screening. Age, race, family history, and overall health are factored into screening decisions.

Historical development

PSA measurement became clinically available in the early 1990s and rapidly became a routine part of prostate health assessment. Over time, evolving guidelines from groups such as the American Urological Association and the National Comprehensive Cancer Network have refined PSA thresholds and recommended schedules for screening, reflecting balance between early detection and avoidance of unnecessary interventions.

This article summarizes current knowledge about the PSAbloedtest and provides a framework for understanding its role in prostate disease management.